Skip to main content
EVMN
NYSE Life Sciences

Evommune的EVO301在2a期AD试验中达到主要终点，获得1.25亿美元私募投资

feedReported by Dow Jones Newswires
Sentiment info
Positive
Importance info
9
Price
$25.09
Mkt Cap
$790.94M
52W Low
$13.885
52W High
$33.2
Market data snapshot near publication time

summarizeSummary

Evommune宣布其EVO301在湿疹的2a期概念验证试验中公布了积极的顶线数据，达到其主要终点，具有统计学意义的EASI降低。这一临床成功是对公司管道的重大验证。同时，Evommune通过1.25亿美元的私募投资加强了其资产负债表，显著延长了其现金跑道到2028年，并为进一步的临床里程碑提供了资本。公司还报告称，其EVO756计划仍按计划在2026年第二季度和下半年分别为慢性自发性荨麻疹和湿疹交付2b期顶线数据。虽然公司报告了2025年第四季度和全年财务结果，但发布中未提供具体数字。这一强大的临床进展和大量融资的结合对这一临床阶段的生物技术公司来说是极为积极的，降低了其开发路径的风险，并支持未来管道的扩张。

在该公告发布时，EVMN的交易价格为$25.09，交易所为NYSE，所属行业为Life Sciences，市值约为$7.9亿。 52周交易区间为$13.89至$33.20。 这则新闻被评估为积极市场情绪，重要性评分为9/10。 来源：Dow Jones Newswires。

show_chartPrice Chart

Share this article

Copied!

feed EVMN - Latest Insights

EVMN
Apr 24, 2026, 4:23 PM EDT
Filing Type: 424B3
Importance Score:
7
Resale Registration Filed for 4.5 Million Shares from Private Placement
Sentiment: Negative
View Wiseek Article
EVMN
Apr 21, 2026, 4:05 PM EDT
Filing Type: DEF 14A
Importance Score:
8
Evommune Secures $125.3M in Private Placement to Fund Clinical Programs
Sentiment: Positive
View Wiseek Article
EVMN
Apr 13, 2026, 4:09 PM EDT
Filing Type: 8-K
Importance Score:
8
Evommune Details Phase 2b Trial for EVO756 in Migraine Prophylaxis
Sentiment: Positive
View Wiseek Article
EVMN
Mar 05, 2026, 4:07 PM EST
Filing Type: 10-K
Importance Score:
9
Evommune Reports Positive Phase 2a EVO301 Data, Secures $125M Financing, Extends Cash Runway to H2 2028
Sentiment: Positive
View Wiseek Article
EVMN
Mar 05, 2026, 4:05 PM EST
Filing Type: 8-K
Importance Score:
8
Evommune Secures $125M Private Placement, Extends Cash Runway Through 2028
Sentiment: Positive
View Wiseek Article
EVMN
Mar 05, 2026, 4:01 PM EST
Source: Dow Jones Newswires
Importance Score:
9
Evommune's EVO301 Hits Primary Endpoint in Phase 2a AD Trial, Secures $125M Private Placement
Sentiment: Positive
View Wiseek Article
EVMN
Feb 19, 2026, 4:30 PM EST
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Institutional Investor LSP 7 Increases Stake in Evommune, Inc. by $10 Million
Sentiment: Positive
View Wiseek Article
EVMN
Feb 17, 2026, 7:28 PM EST
Filing Type: SCHEDULE 13D/A
Importance Score:
7
RA Capital Management Boosts Evommune Stake to 9.7% via $1M Private Placement Purchase
Sentiment: Positive
View Wiseek Article
EVMN
Feb 13, 2026, 8:00 AM EST
Filing Type: 8-K
Importance Score:
8
Evommune Secures $125M Private Placement Following Positive Phase 2a Trial Results
Sentiment: Positive
View Wiseek Article
EVMN
Feb 10, 2026, 8:28 AM EST
Filing Type: 8-K
Importance Score:
9
Evommune Announces Highly Positive Phase 2a Data for EVO301 in Atopic Dermatitis
Sentiment: Positive
View Wiseek Article